Application of mSEPT9 as marker for predicting postoperative recurrence risk of colorectal cancer patient and for evaluating effectiveness of chemotherapy regimen

A colorectal cancer, effective technology, applied in the medical field, can solve the problems of limited sensitivity and specificity, and achieve the effects of excellent sensitivity and specificity, good prediction of recurrence, and prolongation of survival time.

Pending Publication Date: 2022-05-31
TIANJIN PEOPLE HOSPITAL
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Serum tumor biomarkers currently used to monitor tumor recurrence, such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 242 (CA242), have limited sensitivity and specificity , the inventor believes that providing a highly sensitive and specific detection method for predicting recurrence and guiding the selection of chemotherapy regimens needs to be developed urgently

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mSEPT9 as marker for predicting postoperative recurrence risk of colorectal cancer patient and for evaluating effectiveness of chemotherapy regimen
  • Application of mSEPT9 as marker for predicting postoperative recurrence risk of colorectal cancer patient and for evaluating effectiveness of chemotherapy regimen
  • Application of mSEPT9 as marker for predicting postoperative recurrence risk of colorectal cancer patient and for evaluating effectiveness of chemotherapy regimen

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] The patent application will be further described below in conjunction with the accompanying drawings and embodiments.

[0022] This application included 426 stage II and III CRC patients who underwent radical surgery, and collected the following index detection results of patients at six time points before surgery and 1, 3, 6, 9, and 12 months after surgery: mSEPT9, CEA, For CA19-9 and CA242, patients received routine imaging examinations. At the same time, the patients were followed up. The median follow-up time was 15.8 months (range 8.1-43.4 months). The patient's survival, recurrence, treatment plan and other information were recorded. Through χ2 test, COX regression analysis, K-M survival analysis, propensity Matching analysis and other statistical methods were used to analyze the guiding role of mSEPT9 in patient recurrence monitoring and chemotherapy regimen selection.

[0023] 1. DNA Quantification of Methylated SEPT9

[0024] The detection of mSEPT9 gene meth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of mSEPT9 as a marker for predicting the postoperative recurrence risk of a colorectal cancer patient and in evaluating the effectiveness of a chemotherapy regimen. The mSEPT9 disclosed by the invention is remarkably superior to a traditional tumor marker (CEA, CA199 and CA242) in the aspects of sensitivity and specificity on the recurrence risk of a CRC patient, the recurrence prediction of the mSEPT9 is far earlier than that of imaging examination, and the median leading time is 5 months. Moreover, the most suitable patient groups of different chemotherapy regimens can be distinguished by detecting the mSEPT9, the postoperative recurrence of the patients is reduced, and the survival time is prolonged.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to the application of mSEPT9 (methylated SEPT9 DNA) as a marker for predicting postoperative recurrence risk of colorectal cancer patients and for evaluating the effectiveness of chemotherapy regimens. Background technique [0002] Colorectal cancer (CRC) is the second most common malignant tumor in the world. In 2018, more than 1.8 million people were newly diagnosed with CRC and 881,000 people died, ranking second in the mortality rate. The 5-year survival rate of CRC is 64%, but after postoperative recurrence and distant metastasis, the survival rate will drop to 14%, and the 5-year survival rate of patients with liver metastasis is only 6.1%. Surgical radical resection is still the main method for the treatment of colorectal cancer. The guidelines recommend that patients undergo routine clinical evaluation and imaging monitoring after surgery to detect recurrence or metastasis ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6858C12Q1/6886
CPCC12Q1/6858C12Q1/6886C12Q2600/154C12Q2600/106C12Q2600/118C12Q2531/113
Inventor 张春泽张锡朋李国逊詹壹翔倪克民赵轩竹刘兆策袁震王书缘
Owner TIANJIN PEOPLE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap